Becker's Healthcare June 13, 2024
Erica Carbajal

The majority of ACA marketplace plans cover GLP-1 drugs approved for diabetes, though fewer than 1% of plan formularies include drugs solely approved to treat obesity, a new analysis from KFF shows.

The weight loss medication coverage landscape is complex. Numerous insurers, health systems, self-funded employers and state health plans have ended or restricted coverage for weight loss drugs, which can cost upward of $10,000 a year. Most recently, Blue Cross Blue Shield of Michigan moved to drop coverage of GLP-1 drugs for weight loss in fully insured, large group commercial plans.

Novo Nordisk, the manufacturer of Ozempic and Wegovy, has denounced lawmakers’ heightened scrutiny on list prices of the medications, calling it “misplaced and unfair.” The drugmaker...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: ACA (Affordable Care Act), Biotechnology, Insurance, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
Related Articles:
In Their Own Words Marketplace Enrollees Would Struggle to Afford Premium Hikes If Congress
Trump administration targets ACA 'program integrity' with new rule, slashes navigator funding
CMS cuts funding to ACA Navigator program
Eliminating the ACA Medicaid Expansion Match Could Reduce Total Medicaid Spending by Up To $1.9 Trillion Over 10 Years and End Coverage for 20 Million People
GOP calls for $1.5T in cuts, much of which could come from healthcare

Share This Article